Cardinal Health opens the week with analyst focus, shares in S&P 500 healthcare

Cardinal Health starts the new week with a clear analyst lens on its role as a major U.S. healthcare distributor, with the stock part of the S&P 500 and trading on the NYSE.

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-30, 10:49.

Cardinal Health (US14149Y1082) enters the week as one of the larger U.S. healthcare distributors in the S&P 500, with its shares listed on the NYSE and watched closely by retail and institutional investors. The angle for Tuesday is the analyst view and consensus picture on the stock, which frames expectations around margins, cash generation and capital returns.

How analysts view Cardinal Health

Cardinal Health is generally covered by a broad set of Wall Street houses, reflecting its role as a key link in the U.S. drug distribution chain and medical products supply to hospitals and clinics. Many research firms typically focus on its operating margin trends in pharmaceutical distribution, which historically run at low single-digit levels given the high-volume, low-spread nature of the business.

Analyst commentary on Cardinal Health often highlights the balance between margin pressure from generic drug price dynamics and opportunities from specialty pharmaceutical distribution, which tends to carry higher margins and growth. The company’s positioning alongside peers such as McKesson and AmerisourceBergen (now Cencora) gives analysts comparative data points on working capital efficiency, return on invested capital and scale benefits in negotiating with manufacturers.

Consensus themes at the start of the week

Across the typical consensus screens followed by market participants, Cardinal Health is frequently evaluated on earnings stability and free cash flow generation, which are key in distribution models that operate on thin reported margins but large volumes. Many consensus models track revenue growth in the low- to mid-single-digit range over a multi-year horizon, consistent with underlying trends in U.S. pharmaceutical demand and healthcare utilization.

Investors regularly look at consensus estimates for adjusted earnings per share and compare those with the company’s capital allocation choices such as dividends and share repurchases. In recent years, the stock’s role in the S&P 500 healthcare cohort has meant that ETF flows and index-tracking strategies can amplify reactions when consensus estimates are revised, particularly around quarterly reporting dates or guidance updates.

How the company makes its money

Cardinal Health’s core business model is built around pharmaceutical distribution in the United States, where it purchases medications from manufacturers and delivers them to pharmacies, hospitals and other care providers. It also runs a sizable medical products segment, supplying items such as surgical gloves, gowns, and various consumables under its Cardinal Health brand to health systems, ambulatory centers and physicians’ offices.

Where the stock trades today

The Cardinal Health shares (US14149Y1082) trade on the NYSE, with the latest verifiable price on 2026-06-30 at 10:30 New York time around the recent levels seen in the broader S&P 500 healthcare distribution peer group, quoted in U.S. dollars. The exact intraday price can be checked on live exchange and data provider pages at that timestamp.

Cardinal Health at a glance

• Company: Cardinal Health Inc.
• ISIN: US14149Y1082
• WKN: 879312
• Ticker: CAH
• Trading venue: NYSE
• Price (as of 2026-06-30, 10:30): live quote in USD
• Market cap: large-cap range in USD (as of 2026-06-30)
• Sector / industry: Healthcare, pharmaceutical distribution and medical products
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This text is intended solely as neutral stock news and does not contain any investment advice or recommendation to buy or sell securities. Investors should base decisions on their own research or consult a licensed advisor.